---
title: "Soligenix (SNGX) news: reverse split, offering and Nasdaq notice"
url: "https://aibio.space/companies/soligenix/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "SNGX reverse split, offering and Nasdaq notice news: Soligenix stockholders approve reverse split authority and share increase. Soligenix, Inc."
---

SNGX Soligenix, Inc. NASDAQ · United States

# Soligenix (SNGX) news SNGX reverse split, offering and Nasdaq notice news

Listings · 2026-09-17

## [Soligenix stockholders approve reverse split authority and share increase](https://aibio.space/news/soligenix-stockholders-approve-reverse-split-authority-share-increase/)

At its September 17, 2026 annual meeting, stockholders approved a reverse split at a ratio of 1-for-2 to 1-for-20 and raised authorized common shares from 75,000,000 to 125,000,000.

## Latest Soligenix news

1. 2026-06-26 Financings [Soligenix adds $2,500,000 to its at-the-market sales agreement](https://aibio.space/news/soligenix-adds-2-500-000-market-sales-agreement/) Soligenix filed a prospectus supplement raising the maximum under its January 23, 2026 sales agreement with Rodman & Renshaw LLC by $2,500,000.
2. 2026-06-12 Listings [Soligenix gets Nasdaq minimum bid price notice, ends HyBryte program](https://aibio.space/news/soligenix-gets-nasdaq-minimum-bid-price-notice-ends-hybryte-program/) Nasdaq told Soligenix on June 10, 2026 that its stock has closed below the $1.00 minimum bid price, and the company has until December 7, 2026 to regain compliance. Its board then ended the HyBryte development program, after an interim analysis in a Phase 3 trial recommended stopping it for futility.
3. 2026-05-28 Financings [Soligenix adds $2,956,000 to its at-the-market sales agreement](https://aibio.space/news/soligenix-adds-2-956-000-market-sales-agreement/) Soligenix filed a prospectus supplement raising the maximum under its January 23, 2026 sales agreement with Rodman & Renshaw LLC by $2,956,000.
4. 2026-04-28 Company Updates [Soligenix FLASH 2 trial recommended to halt for futility](https://aibio.space/news/soligenix-flash-2-trial-recommended-halt-futility/) After an interim efficacy analysis, the Data Monitoring Committee recommended stopping the Phase 3 HyBryte trial for futility, and Soligenix says it has approximately $5.9 million of cash.
5. 2025-11-18 Listings [Soligenix regains Nasdaq stockholders' equity compliance after August notice](https://aibio.space/news/soligenix-regains-nasdaq-stockholders-equity-compliance-after-august/) Nasdaq told Soligenix on November 18, 2025 that the matter is closed. The company reported stockholders' equity of $7,597,976 for the quarter ended September 30, 2025, against a $2,500,000 requirement.
6. 2025-09-19 Financings [Soligenix prices $7.5 million public offering of shares and warrants at $1.35](https://aibio.space/news/soligenix-prices-7-5-million-public-offering-shares-warrants-1-35/) The offering covers 5,555,560 shares or equivalents with matching five-year warrants. Soligenix also cut the exercise price on 1,162,064 older warrants to $1.35.
7. 2025-08-15 Listings [Soligenix gets Nasdaq notice for stockholders' equity below $2,500,000](https://aibio.space/news/soligenix-gets-nasdaq-notice-stockholders-equity-below-2-500-000/) Soligenix reported stockholders' equity of $1,828,951 at June 30, 2025 and has until September 29, 2025 to submit a plan to regain compliance with the Nasdaq minimum.

## Soligenix at a glance

- **Ticker**: SNGX

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $9.8 million

### Related companies

- [Citius Oncology](https://aibio.space/companies/citius-oncology/) NASDAQ: CTOR
- [Artelo Biosciences](https://aibio.space/companies/artelo-biosciences/) NASDAQ: ARTL
- [Neumora Therapeutics](https://aibio.space/companies/neumora-therapeutics/) NASDAQ: NMRA
- [Panbela Therapeutics](https://aibio.space/companies/panbela-therapeutics/) OTC: PBLA
- [Dare Bioscience](https://aibio.space/companies/dare-bioscience/) NASDAQ: DARE
- [Karyopharm Therapeutics](https://aibio.space/companies/karyopharm-therapeutics/) NASDAQ: KPTI
- [Vyome Holdings](https://aibio.space/companies/vyome/) NASDAQ: HIND
- [CytomX Therapeutics](https://aibio.space/companies/cytomx-therapeutics/) NASDAQ: CTMX

### Also on NASDAQ

- [Electra Therapeutics](https://aibio.space/companies/electra-therapeutics/) ETRA
- [Entera Bio](https://aibio.space/companies/entera-bio/) ENTX
- [vTv Therapeutics](https://aibio.space/companies/vtv-therapeutics/) VTVT
- [Aclarion](https://aibio.space/companies/aclarion/) ACON
- [Zevra Therapeutics](https://aibio.space/companies/zevra-therapeutics/) ZVRA
- [Tonix Pharmaceuticals Holding](https://aibio.space/companies/tonix-pharmaceuticals/) TNXP

## What Soligenix does

Soligenix, Inc. is a late-stage biopharmaceutical company developing and commercializing products for rare diseases with unmet medical need. It has two business segments. Specialized BioTherapeutics is developing HyBryte, a proposed name for synthetic hypericin, as a photodynamic therapy for cutaneous T-cell lymphoma. The first Phase 3 FLASH study reported positive primary endpoint results, and enrollment in a second Phase 3 study, FLASH2, began in December 2024, with top-line results anticipated in the second half of 2026. This segment also develops synthetic hypericin for psoriasis and dusquetide for aphthous ulcers in Behçet's Disease and for oral mucositis in head and neck cancer. Public Health Solutions develops RiVax, a ricin toxin vaccine candidate, a therapeutic candidate for emerging infectious diseases, filovirus vaccine programs and CiVax for COVID-19, using its ThermoVax heat stabilization platform. Development has been supported by government grant and contract funding from the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority and the Defense Threat Reduction Agency.

| Product or program | What it is | Stage |
|---|---|---|
| HyBryte (synthetic hypericin) | Photodynamic therapy using topical synthetic hypericin for cutaneous T-cell lymphoma | Second Phase 3 (FLASH2) enrolling; top-line results anticipated in the second half of 2026 |
| SGX302 | Synthetic hypericin expansion for mild-to-moderate psoriasis | Phase 2a ongoing |
| SGX945 (dusquetide) | Innate Defense Regulator for aphthous ulcers in Behçet's Disease | Phase 2a complete |
| SGX942 (dusquetide) | Innate Defense Regulator for oral mucositis in head and neck cancer | Second Phase 3 needed; contingent on identifying a partner |
| RiVax | Ricin toxin vaccine candidate | Phase 1a, 1b and 1c trials completed |

Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/sngx-20251231x10k.htm).

## Soligenix annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue |  | [$119,371](https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/) |
| Research and development | [$7.5 million](https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/) | [$5.2 million](https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/) |
| Net income (loss) | [-$11.1 million](https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/) | [-$8.3 million](https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/) |
| Cash from operations | [-$10.3 million](https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/) | [-$8.4 million](https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/) |
| Cash and equivalents | [$7.9 million](https://www.sec.gov/Archives/edgar/data/812796/000110465926092681/) | [$7.8 million](https://www.sec.gov/Archives/edgar/data/812796/000110465926092681/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $9.8 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Soligenix

Did Soligenix do a reverse stock split?

Our latest story on this, dated Sep 17, 2026: "Soligenix stockholders approve reverse split authority and share increase". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/soligenix-stockholders-approve-reverse-split-authority-share-increase/).

Has Soligenix raised money recently?

Our latest story on this, dated Jun 26, 2026: "Soligenix adds $2,500,000 to its at-the-market sales agreement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/soligenix-adds-2-500-000-market-sales-agreement/).

Has Soligenix received a Nasdaq deficiency notice?

Our latest story on this, dated Aug 15, 2025: "Soligenix gets Nasdaq notice for stockholders' equity below $2,500,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/soligenix-gets-nasdaq-notice-stockholders-equity-below-2-500-000/).

What is the ticker symbol of Soligenix?

Soligenix, Inc. trades under the ticker SNGX on NASDAQ.

Where is Soligenix listed?

Soligenix, Inc. is listed on NASDAQ. Our directory also records these other listings: LSE:0A6I.

What is the SEC CIK of Soligenix?

The SEC Central Index Key (CIK) for Soligenix, Inc. is 812796. Its filings are on SEC EDGAR.

How many shares does Soligenix have outstanding?

21,765,479 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-07.

Which country or territory is Soligenix listed under?

Our directory records Soligenix, Inc. under United States.

What does Soligenix do?

Our directory classifies Soligenix, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Soligenix?

The ISIN recorded for Soligenix, Inc. is US8342236044.

Does aibio.space cover Soligenix?

aibio.space lists Soligenix, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Soligenix incorporated?

SEC records list its state or country of incorporation as DE.

What does Soligenix develop?

Soligenix, Inc. is a late-stage biopharmaceutical company developing and commercializing products for rare diseases with unmet medical need. It has two business segments.

What is HyBryte (synthetic hypericin) from Soligenix?

HyBryte (synthetic hypericin): Photodynamic therapy using topical synthetic hypericin for cutaneous T-cell lymphoma Stage: Second Phase 3 (FLASH2) enrolling; top-line results anticipated in the second half of 2026.

What is SGX302 from Soligenix?

SGX302: Synthetic hypericin expansion for mild-to-moderate psoriasis Stage: Phase 2a ongoing.

## Investor discussion: Soligenix

Members talk about Soligenix (SNGX). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Soligenix, newest first. Each line links the filing it comes from.

1. 2026-09-21 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/812796/000110465926109329/sngx-20260917x8k.htm)
2. 2026-08-03 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/812796/000110465926089789/tm261557-7_def14a.htm)
3. 2026-07-21 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/812796/000110465926085423/tm261557-3_pre14a.htm)
4. 2026-06-26 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/812796/000110465926078241/sngx-20260626x424b5.htm)
5. 2026-06-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/sngx-20260610x8k.htm)
6. 2025-11-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/812796/000110465925113645/sngx-20251118x8k.htm)
7. 2025-09-19 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/812796/000110465925091717/sngx-20250630xs1.htm)
8. 2025-08-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/812796/000155837025011619/sngx-20250815x8k.htm)
9. 2025-02-10 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/812796/000155837025000726/sngx-20250205x8k.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SNGX on TradingView](https://www.tradingview.com/symbols/NASDAQ-SNGX/).

## SEC filings and registration

- **SEC name**: Soligenix, Inc.

- **CIK**: 812796

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: SNGX (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 29 EMMONS DRIVE, PRINCETON, NJ, 08540

- **Phone**: 609-538-8200

- **Shares outstanding**: 21,765,479 as of 2026-07-31 (10-Q filed 2026-08-07)

- **Former names**: SOLIGENIX, INC.; DOR BIOPHARMA INC; ENDOREX CORP

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/812796/000110465926109329/sngx-20260917x8k.htm) filed 2026-09-21
- [10-Q](https://www.sec.gov/Archives/edgar/data/812796/000110465926092681/sngx-20260630x10q.htm) filed 2026-08-07
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/812796/000110465926089789/tm261557-7_def14a.htm) filed 2026-08-03
- [8-K](https://www.sec.gov/Archives/edgar/data/812796/000110465926078251/sngx-20260626x8k.htm) filed 2026-06-26
- [424B5](https://www.sec.gov/Archives/edgar/data/812796/000110465926078241/sngx-20260626x424b5.htm) filed 2026-06-26
- [8-K](https://www.sec.gov/Archives/edgar/data/812796/000110465926073430/sngx-20260610x8k.htm) filed 2026-06-12
- [8-K](https://www.sec.gov/Archives/edgar/data/812796/000110465926067649/sngx-20260528x8k.htm) filed 2026-05-28
- [424B5](https://www.sec.gov/Archives/edgar/data/812796/000110465926067644/sngx-20260528x424b5.htm) filed 2026-05-28

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000812796), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Soligenix, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SNGX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Soligenix, Inc.

- **Ticker**: SNGX

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US8342236044

- **Other listed symbols**: LSE:0A6I

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SNGX/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/soligenix/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Soligenix (SNGX) news: reverse split, offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/soligenix/